Anaplastic Thyroid Cancer with Brain Metastases and Neurologic Compressive Symptoms
Brain metastases in anaplastic thyroid cancer can produce significant neurologic compressive symptoms or signs that require prompt, structured management. This protocol addresses that specific clinical presentation.
Clinical Scenario
Patients with anaplastic thyroid cancer who develop brain metastases accompanied by neurologic brain compressive symptoms or signs. The presence of mass effect and the degree of cranial symptom severity guide the initial approach.
Treatment Approach (partial overview)
Management involves corticosteroid therapy to address mass effect and neurologic symptoms, with the dose guided by symptom severity. This is combined with referral to neurosurgery and radiation oncology for evaluation of surgical resection and radiation-based interventions targeting the brain metastases.
Full regimen details, dosing guidance, and decision algorithm available in the complete protocol →
Clinical goal: Improvement in neurological symptoms.
References
- In ATC patients with neurologic brain compressive symptoms or signs, we recommend dexamethasone (4–16 mg/day).
- Ryken et al. published guidelines for patients with brain metastases from a variety of different tumors, recommending that patients with brain metastases with mass effect be treated with 4–8 mg/day of dexamethasone as the initial dose.
- Patients with moderate to severe cranial symptoms should be considered to receive 16 mg/day (generally 4 mg, four times daily).
- In ATC patients with brain metastases, referral to neurosurgery/radiation oncology should be made.
- Multiple lesions not amenable to stereotactic radiotherapy should instead be treated with whole-brain radiation therapy, else the patient should be referred to hospice care.
- Surgical treatment resulted in improvement in quality of life and improvement in neurological symptoms.
DOI: 10.1089/thy.2020.0944
View source ↗